Early development of broadly neutralizing antibodies in HIV-1-infected infants

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 655-658

  Goo, Leslie ^a,b   Chohan, Vrasha ^a   Nduati, Ruth ^c   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; VERTICAL TRANSMISSION; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGE FACTORS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; KENYA; LINEAR MODELS; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION;

EID: 84902131373     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3565     Document Type: Article

References (34)

1. Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
2. + T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
3. Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).
4. Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009).
5. Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83, 10269-10274 (2009).
6. van Gils, M.J., Euler, Z., Schweighardt, B., Wrin, T. & Schuitemaker, H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23, 2405-2414 (2009).
7. Doria-Rose, N.A. et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636 (2010).
8. Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163-169 (2014).
9. Richardson, B.A. et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J. Virol. 77, 7120-7123 (2003). (Pubitemid 36666906)
10. Siegrist, C.A. Neonatal and early life vaccinology. Vaccine 19, 3331-3346 (2001).
11. Nduati, R. et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. J. Am. Med. Assoc. 283, 1167-1174 (2000). (Pubitemid 30126605)
12. Seaman, M.S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
13. Cortez, V., Odem-Davis, K., McClelland, R.S., Jaoko, W. & Overbaugh, J. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog. 8, e1002611 (2012).
14. Blish, C.A., Nedellec, R., Mandaliya, K., Mosier, D.E. & Overbaugh, J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21, 693-702 (2007). (Pubitemid 46568626)
15. Blish, C.A. et al. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J. Virol. 83, 7783-7788 (2009).
16. Wu, X. et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80, 835-844 (2006). (Pubitemid 43062895)
17. Lynch, J.B. et al. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J. Virol. 85, 5252-5261 (2011).
18. Blish, C.A., Nguyen, M.-A. & Overbaugh, J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5, e9 (2008).
19. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
20. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470. 10.1038/nature10373 (2011).
21. Wu, X. et al. rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
22. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
23. Georgiev, I.S. et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013).
24. Scharf, O. et al. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J. Virol. 75, 6558-6565 (2001). (Pubitemid 32578175)
25. Cavacini, L.A. et al. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J. Immunol. 155, 3638-3644 (1995).
26. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000). (Pubitemid 30082366)
27. Ng, C.T. et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16, 1117-1119 (2010).
28. Levesque, M.C. et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 6, e1000107 (2009).
29. Hoffenberg, S. et al. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J. Virol. 87, 5372-5383 (2013).
30. Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490 (2013).
31. Julien, J.-P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 110, 4351-4356 (2013).
32. Sanders, R.W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
33. Moore, P.L. et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692. 10.1038/nm.2985 (2012).
34. Neilson, J.R. et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 73, 4393-4403 (1999). (Pubitemid 29189886)